INCB13739   Click here for help

GtoPdb Ligand ID: 12121

Synonyms: Compound 39 [PMID: 35537608]
Compound class: Synthetic organic
Comment: INCB13739 is an orally bioavailable, nonsteroidal inhibitor of 11β-hydroxysteroid dehydrogenase 1 (11-βHSD1; HSD11B1) [1]. It is a clinical lead for the control of glucose levels in the treatment of type 2 diabetes mellitus.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 88.6
Molecular weight 467.18
XLogP 3.52
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CNC(=O)c1ccc(cn1)c1ccc(cc1)C1(CC1)C(=O)N1CC[C@@]2(C1)OC(=O)c1c2cccc1
Isomeric SMILES N(C)C(=O)c1ccc(cn1)c1ccc(cc1)C1(CC1)C(=O)N1CC[C@@]2(C1)OC(=O)c1c2cccc1
InChI InChI=1S/C28H25N3O4/c1-29-24(32)23-11-8-19(16-30-23)18-6-9-20(10-7-18)27(12-13-27)26(34)31-15-14-28(17-31)22-5-3-2-4-21(22)25(33)35-28/h2-11,16H,12-15,17H2,1H3,(H,29,32)/t28-/m0/s1
InChI Key BDQCDIWFPIDPQU-NDEPHWFRSA-N
No information available.
Summary of Clinical Use Click here for help
INCB13739 has progressed to phase 2 clinical trial.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00398619 A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes Phase 1 Interventional Incyte Corporation
NCT00478322 Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects Phase 2 Interventional Incyte Corporation
NCT00698230 Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics Phase 2 Interventional Incyte Corporation 1